Saturday, January 18, 2025 8:40:44 PM
“What I expect to happen is a jump in share price followed by rampant short selling”.
— I agree with the above statement but not the reasons you gave for short selling. Short selling will happen because they know LP has nothing meaningful up her sleeve post approval except fluff PRs like Oncovir partnership, combo trial (but no cash to run and accelerate it), and so on, so it would be easy money for them again.
I do agree that the only news that will get shorts to move away from their games and give up will be a validation from big pharma including cash injection. Outside that, nothing else will matter and they will continue to question every move and short at every opportunity. It doesn’t help that this management team has a really bad history and have lost investors ton of money and opportunity cost over the last 10-15 years.
— I agree with the above statement but not the reasons you gave for short selling. Short selling will happen because they know LP has nothing meaningful up her sleeve post approval except fluff PRs like Oncovir partnership, combo trial (but no cash to run and accelerate it), and so on, so it would be easy money for them again.
I do agree that the only news that will get shorts to move away from their games and give up will be a validation from big pharma including cash injection. Outside that, nothing else will matter and they will continue to question every move and short at every opportunity. It doesn’t help that this management team has a really bad history and have lost investors ton of money and opportunity cost over the last 10-15 years.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
